AA 2414
Seratrodast
CAS: 112665-43-7
Molecular Formula: C22H26O4
AA 2414 - Names and Identifiers
AA 2414 - Physico-chemical Properties
| Molecular Formula | C22H26O4 |
| Molar Mass | 354.44 |
| Density | 1.140±0.06 g/cm3(Predicted) |
| Melting Point | 118-120°C |
| Boling Point | 522.3±49.0 °C(Predicted) |
| Flash Point | 128.336°C |
| Solubility | Chloroform (Slightly), Methanol (Slightly) |
| Vapor Presure | 0.002mmHg at 25°C |
| Appearance | Pale orange solid |
| Color | Pale Orange to Yellow |
| Merck | 14,8459 |
| pKa | 4.76±0.10(Predicted) |
| Storage Condition | Sealed in dry,Store in freezer, under -20°C |
| Refractive Index | 1.584 |
| Physical and Chemical Properties | Crystallized from ethanol, melting point 128-129 ℃. |
| Use | Used as antiasthmatic drug |
AA 2414 - Risk and Safety
| RTECS | DA1600050 |
AA 2414 - Nature
Open Data Verified Data
crystallized from ethanol, melting point 128-129 °c.
Last Update：2024-01-02 23:10:35
AA 2414 - Preparation Method
Open Data Verified Data
2,3, 5-trimethylhydroquinone and 7-hydroxyphenylheptanoic acid are dissolved in toluene, D-camphor -10-sulfonic acid is added, the reaction is stirred at 70 ℃, the reaction solution is concentrated, the resulting material was oxidized with a 10% aqueous solution of ferric chloride. After treatment, the product was obtained by re-chromatography.
Last Update：2022-01-01 09:23:04
AA 2414 - Use
Open Data Verified Data
developed by Takeda in Japan, it was launched in Japan in 1996. Sertrast is a TXA2 receptor antagonist, can be used for bronchial asthma and Cough, sputum and other symptoms of the treatment.
Last Update：2022-01-01 09:23:05
AA 2414 - Reference Information
| Overview | tracheal asthma is caused by eosinophils, mast cells and T lymphocytes and other inflammatory cells are involved in chronic allergic airway diseases. In recent years, important progress has been made in the pathogenesis of Asthma. It has been recognized that thromboxane, prostaglandin, platelet activating factor and other inflammatory mediators cause airway mucosal edema, inflammatory cell infiltration, increased glandular secretion and obstruction of intraluminal mucus plug are also important mechanisms of asthma. Therefore, attention has been paid to the development and application of anti-asthma drugs for the above-mentioned inflammatory mediators. At present, the clinical treatment of asthma mainly depends on the administration of steroidal anti-inflammatory drugs and the combined use of bronchodilators. The effect of steroidal anti-inflammatory drugs in the treatment of asthma is affirmative, but its effect is too wide, the lack of specificity, long-term use can make the hypothalamus pituitary secretion of corticotropin is inhibited, and can make the skin thinning, bone loss, the use of children and even lead to growth inhibition and so on. In addition, some patients with asthma have resistance to steroidal anti-inflammatory drugs. Bronchodilators also have major side effects when administered at high doses. Therefore, there is an urgent need for new anti-asthma drugs, which should have the characteristics of reliable action, high safety, convenient administration and patient compliance. Among them, thromboxane A(TXA2) the treatment of the receptor antagonist, sertrast, has received considerable attention. Seratroast (trade name Bronica), is an orally effective non-prostanoid thromboxane A2/prostate H2(TXA2/ PGH2) receptor blocker that inhibits the activity of PGH2 analogs, leukotriene D4(LTD4) and platelet activating factor (PAF) are responsible for allergic asthma, which was launched in Japan by Takeda Corporation in 1995. Sertrast not only antagonized the effects of TXA2, but also antagonized other COX-line metabolites. It can not only inhibit the bronchoconstriction induced by U-46619 in guinea pigs, but also inhibit the immediate and late asthma response and reduce the airway hyperresponsiveness in dogs. In addition, studies have found that it can also antagonize choline or methacholine acetate induced asthma. Studies have shown that it can inhibit bronchoconstriction caused by platelet activating factor (PAF), leukotriene (LT), etc. in vivo, and has entered the Japanese asthma prevention guidelines. |
| pharmacological effects | the immediate and delayed allergic reactions caused by sertrastast to guinea pigs by inhalation of antigen, such as increased tracheal resistance, altitude sickness, etc, on the lgG1 and lgE to the guinea pig bronchoconstriction, for various chemicals including PGD2, LTD4, PAF induced tracheal contraction in guinea pigs and Ascaris naturally sensitized hybrid dogs due to inhalation of antigen induced tracheal hyperresponsiveness has a significant inhibitory effect, infiltration of the airways by inflammatory cells is also reduced by inhibiting the expression of chemokines in bronchial tissue. Figure 1 shows the structural formula |
| toxicological studies | 1. Acute Toxicity Study: Male and female mice were gavage with sertraxast with LD50 of 1650mg/kg and 1520mg/kg, respectively. In male and female mice, LD50 were 1360mg/kg and 100mg/kg, respectively. Both mice and rats were injected subcutaneously with LD50 greater than 5000mg/kg. The LD50 for male and female rats was 3750-5000mg/kg and 5000mg/kg, respectively. In male and female rats, LD50 were 1770mg/kg and 1350mg/kg, respectively. 2. Long-term toxicity study: the non-toxic dose for rats was 10 mg/kg/d for 52 weeks, and the non-toxic dose for beagle dogs was 30 mg/kg/d for 52 weeks. 3. Mutagenicity and reproductive toxicity test: male rats were orally administered with 30 mg/kg/d of sertrast, without side effect on the parents, and were orally administered with 100 mg/kg/d for the reproductive function of the parents, the formation and development of fetal rats were not affected. Female rabbits oral sertrast 30 mg/kg/d, found no abnormal phenomenon to the parent, the dose of up to 100 mg/kg/d and no stillbirth and teratogenic effect. |
| pharmacokinetics | after oral administration, sertrastast is mainly absorbed from the small intestine through the portal vein and metabolized in the liver, the main metabolites of the Monkey are heptanoic acid derivatives, hydroxylation products on the side chain benzene ring and hydroxylation products of the methyl group on the benzoquinone ring. Rats and dogs are excreted from the feces with bile, while guinea pigs and monkeys are excreted from the urine. The 72-hour fecal excretion rate of rats was 97%; The dog was 90%; The 96-hour urinary excretion rate of guinea pigs was 60%; The monkey 168-hour urinary excretion rate was 48%. |
| adverse reactions | 1. Very few patients see accompanied by jaundice, ALT, AST elevated liver dysfunction, there are reported patients with acute hepatitis. 2. A small number of patients may appear: allergic symptoms such as rash, itching, can be discontinued treatment; Digestive system diseases such as Nausea, Vomit, loss of appetite, stomach discomfort, Abdominal Pain, Diarrhea, constipation, thirst; blood system diseases such as epistaxis, subcutaneous hemorrhage, anemia, eosinophilia; Mental system diseases such as drowsiness, Head Pain, dizziness and so on. The summary, pharmacological effects, toxicological studies and adverse reactions of sertrastast are compiled by Wang Xuyan. (2016-6-16) |
| drug interaction | 1. Drugs that can cause hemolytic anemia include antipyretic, anti-inflammatory and analgesic drugs such as phenacetin and cephalosporins. 2. After adding aspirin, the free concentration of this product increased by 26%, and the dose should be adjusted when using it. |
| combined use of | the combination of sertrast and budesonide in the treatment of bronchial asthma can inhibit the synthesis and secretion of a variety of inflammatory mediators, promote the expression of a variety of anti-inflammatory factors, prevent the directed transfer and activation of inflammatory cells, affect T lymphocyte activation, CD4 / CD8 and NK cell levels, regulate immune imbalance, improve lung function, clinical symptoms were relieved. The combination of sertrast and budesonide has broad application prospects in the treatment of bronchial asthma. |
| Chemical properties | crystallized from ethanol, melting point 128-129 °c. |
| Use | thromboplastin A2 antagonist. For the treatment of asthma. used as Antiasthmatic agent |
| production method | 2,3, 5-trimethylhydroquinone (I) and 7-hydroxyphenylheptanoic acid (II) are dissolved in toluene, D-camphor -10-sulfonic acid was added and stirred for 20h at 70 °c. After the reaction solution was concentrated, the residue was oxidized with a 10% ferric chloride aqueous solution. After treatment, the product was obtained by re-chromatography. |
Last Update：2024-04-10 22:29:15
Supplier List
Multiple SpecificationsSpot supply
Product Name: Seratrodast Visit Supplier Webpage Request for quotationCAS: 112665-43-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Multiple SpecificationsSpot supply
Product Name: Seratrodast Visit Supplier Webpage Request for quotationCAS: 112665-43-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History